We are an established specialty pharmaceutical company with a strong portfolio consisting of 10 specialist hospital products.

With a strong focus on oncology, oncology supportive care and critical care complemented by a highly developed U.S. commercial infrastructure, broad pan-European coverage and a far-reaching distributor network, we are experiencing significant success in over 80 countries.

There are more than 60 clinical studies evaluating the efficacy of Collatamp for the treatment or prevention of SSIs across a wide variety of surgical procedures including GI/Colorectal, orthopaedic, cardiothoracic, vascular and others.

Our new, comprehensive global website for Caphosol provides a highly informative resource for oral mucositis and Caphosol. Simpler and faster, Caphosol.com provides much richer information, more supporting data and useful handouts with real stories from patients who have experienced oral mucositis.

If you or someone you know are suffering oral mucositis then Caphosol.com may be what you're looking for.

A refreshingly innovative approach to simplifying the "science" and treatment of Oral Mucositis (OM is a particularly nasty and painful side effect of some cancer therapies).

MouthsMadeGood.com is available in 14 languages and our most sought after internet resource.

In this short video, Dr Tim Corn, Chief Medical Officer at EUSA Pharma, explains the benefits this approval will bring to patients in the US with Acute Lymphoblastic Leukemia and EUSA Pharma’s continued commitment to rare diseases.

Watch the video… Read the News…